跳至主要内容
临床试验/NCT00200746
NCT00200746撤回2 期

Arginine Treatment for Alcoholic Hepatitis

National Center for Complementary and Integrative Health (NCCIH)1 个研究点 分布在 1 个国家开始时间: 2006年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
试验地点
1
主要终点
Percent reduction in liver endotoxin production

研究概览

简要总结

The purpose of this study is to test the effectiveness of the amino acid arginine in reducing liver injury in individuals with alcohol-related hepatitis.

详细描述

Arginine is a naturally occurring amino acid that is also available in pill form. Arginine pills have been shown to aid in liver detoxification and fat breakdown in the liver. Numerous studies have examined the effects of arginine on the liver. However, few have determined the optimal concentration of arginine that would best prevent injury to the liver This study will provide participants with three concentration levels of arginine to determine which is most effective in reducing liver injury in alcoholic hepatitis patients.

This study will last 31 days. Participants will be admitted to the General Clinical Research Center for 27 days. Participants will be randomly assigned to one of four groups. Participants in Groups 1, 2, and 3 will have 1%, 2%, or 6% arginine added to their diet in the form of gel capsules. Participants in Group 4 will receive placebo capsules. Participants will be given 24 capsules of different dietary supplements, including the arginine supplements, every day during their hospital stay.

Participants who are not able to ingest at least 18 capsules per day over 3 days or who are not able to eat the majority of their solid or liquid diet while hospitalized will have a naso-gastric soft feeding tube inserted for food and supplements to be administered. A liver biopsy will be performed on Days 3 and 26. The biopsies will involve insertion of a catheter in a neck vein and a small sample of liver tissue will be removed. On Days 2 and 25, participants will undergo blood and urine collection. Participants will also be infused with nonradioactive leucine to determine the levels of albumin, a protein that is reduced in diseased livers. If participants develop fluid in the abdomen (a condition known as ascites), a small sample of fluid will be extracted from the abdomen twice a day on Days 2, 17, and 25. On Day 31, participants will return to the research center for additional blood and urine collection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of alcoholic hepatitis
  • Maddrey's DF score less than 33

排除标准

  • Hepatitis C or B virus infected
  • HIV infected
  • History of cancer
  • Hepatic encephalopathy (a condition in which liver failure affects the central nervous system)
  • Kidney failure
  • A Do Not Resuscitate order (a patient-directed order not to resuscitate in the event that resuscitation is necessary to prevent death)
  • Maddrey's DF score of 33 or greater after vitamin K administration during the study
  • Alcohol withdrawal at study entry
  • Active pneumonia at study entry
  • Allergy to iodine
  • Enrollment in any other clinical trials

研究组 & 干预措施

2

Experimental

Moderate Arginine

干预措施: Arginine (Drug)

3

Sham Comparator

Polycose control arm

干预措施: Arginine (Drug)

1

Experimental

High Arginine

干预措施: Arginine (Drug)

结局指标

主要结局

Percent reduction in liver endotoxin production

时间窗: After nutritional intervention

change in Maddrey's discriminant function (DF) score

时间窗: After nutritional intervention

次要结局

未报告次要终点

研究者

研究点 (1)

Loading locations...

相似试验